

Piero Pollesello

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/954500/piero-pollesello-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122
papers

4,708
citations

41
h-index

64
g-index

129
ext. papers

5,310
ext. citations

4.2
avg, IF

4.99
L-index

#	Paper	IF	Citations
122	Levosimendan in Europe and China: An Appraisal of Evidence and Context. <i>European Cardiology Review</i> , 2021 , 16, e42	3.9	
121	Levosimendan-induced venodilation is mediated by opening of potassium channels. <i>ESC Heart Failure</i> , 2021 ,	3.7	2
120	Haemodynamic Effects of Levosimendan in Outpatients with Advanced Heart Failure: An Echocardiographic Pilot Study. <i>Journal of Cardiovascular Pharmacology</i> , 2021 ,	3.1	1
119	An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. <i>Expert Review of Cardiovascular Therapy</i> , 2021 , 19, 325-335	2.5	4
118	Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 76, 4-22	3.1	12
117	Levosimendan Improves Oxidative Balance in Cardiogenic Shock/Low Cardiac Output Patients. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	8
116	Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. <i>Cardiac Failure Review</i> , 2020 , 6, e19	4.2	15
115	Facing up to the challenges of acute heart failure. <i>European Heart Journal Supplements</i> , 2020 , 22, D1-D2	1.5	
114	Differential effects of inotropes and inodilators on renal function in acute cardiac care. <i>European Heart Journal Supplements</i> , 2020 , 22, D12-D19	1.5	2
113	Short-term treatments for acute cardiac care: inotropes and inodilators. <i>European Heart Journal Supplements</i> , 2020 , 22, D3-D11	1.5	4
112	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. <i>International Journal of Cardiology</i> , 2019 , 297, 83-90	3.2	21
111	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019 , 21, 272-285	12.3	99
110	Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper. <i>Journal of Cardiovascular Pharmacology</i> , 2019 , 73, 3-14	3.1	22
109	Novel Na/Ca Exchanger Inhibitor ORM-10962 Supports Coupled Function of Funny-Current and Na/Ca Exchanger in Pacemaking of Rabbit Sinus Node Tissue. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1632	5.6	6
108	Effects of Levosimendan on Inflammation and Oxidative Stress Pathways in a Lipopolysaccharide-Stimulated Human Endothelial Cell Model. <i>Biological Research for Nursing</i> , 2019 , 21, 466-472	2.6	4
107	Short-Term Therapies for Treatment of Acute and Advanced Heart Failure-Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	9
106	Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan. <i>Cardiac Failure Review</i> , 2019 , 5, 155-161	4.2	8

105	Long-term effects of Na /Ca exchanger inhibition with ORM-11035 improves cardiac function and remodelling without lowering blood pressure in a model of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019 , 21, 1543-1552	12.3	12
104	The Novel Inodilator ORM-3819 Relaxes Isolated Porcine Coronary Arteries: Role of Voltage-Gated Potassium Channel Activation. <i>Journal of Cardiovascular Pharmacology</i> , 2019 , 74, 218-224	3.1	2
103	Potential of the Cardiovascular Drug Levosimendan in the Management of Amyotrophic Lateral Sclerosis: An Overview of a Working Hypothesis. <i>Journal of Cardiovascular Pharmacology</i> , 2019 , 74, 389-399	3.1	8
102	Complex electrophysiological remodeling in postinfarction ischemic heart failure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E3036-E3044	11.5	51
101	Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice. <i>Journal of Cardiovascular Pharmacology</i> , 2018 , 71, 1-9	3.1	39
100	Inotropic effect of NCX inhibition depends on the relative activity of the reverse NCX assessed by a novel inhibitor ORM-10962 on canine ventricular myocytes. <i>European Journal of Pharmacology</i> , 2018 , 818, 278-286	5.3	6
99	Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. <i>Journal of Cardiovascular Pharmacology</i> , 2018 , 71, 129-136	3.1	23
98	Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 617-624	3.9	30
97	Use of levosimendan in acute heart failure. <i>European Heart Journal Supplements</i> , 2018 , 20, I2-I10	1.5	21
96	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. <i>European Heart Journal</i> , 2018 , 39, 4243-4254	9.5	113
95	Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. <i>International Journal of Cardiology</i> , 2017 , 243, 389-395	3.2	21
94	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2017 , 19, 1361-1378	12.3	73
93	Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials. <i>ESC Heart Failure</i> , 2017 , 4, 595-604	3.7	29
92	Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 1335-1347	2.5	11
91	Calcium sensitizers: What have we learned over the last 25 years?. <i>International Journal of Cardiology</i> , 2016 , 203, 543-8	3.2	46
90	Levosimendan meta-analyses: Is there a pattern in the effect on mortality?. <i>International Journal of Cardiology</i> , 2016 , 209, 77-83	3.2	64
89	Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case. <i>Journal of Medical Economics</i> , 2016 , 19, 506-14	2.4	2
88	The Effect of a Novel Highly Selective Inhibitor of the Sodium/Calcium Exchanger (NCX) on Cardiac Arrhythmias in In Vitro and In Vivo Experiments. <i>PLoS ONE</i> , 2016 , 11, e0166041	3.7	32

87	ORM-3819 promotes cardiac contractility through Ca(2+) sensitization in combination with selective PDE III inhibition, a novel approach to inotropy. <i>European Journal of Pharmacology</i> , 2016 , 775, 120-9	5.3	3
86	The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion. <i>International Journal of Cardiology</i> , 2016 , 218, 150-157	3.2	47
85	Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients. <i>International Journal of Cardiology</i> , 2016 , 215, 26-31	3.2	11
84	Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. <i>International Journal of Cardiology</i> , 2016 , 222, 303-312	3.2	78
83	The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. <i>International Journal of Cardiology</i> , 2015 , 191, 256-64	3.2	94
82	Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. <i>International Journal of Cardiology</i> , 2015 , 184, 323-336	3.2	70
81	Pharmaco-economics of levosimendan in cardiology: a European perspective. <i>International Journal of Cardiology</i> , 2015 , 199, 337-41	3.2	17
80	Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay. <i>PLoS ONE</i> , 2015 , 10, e0124742	3.7	22
79	Levosimendan alone and in combination with valsartan prevents stroke in Dahl salt-sensitive rats. <i>European Journal of Pharmacology</i> , 2015 , 750, 132-40	5.3	5
78	Selective Na(+) /Ca(2+) exchanger inhibition prevents Ca(2+) overload-induced triggered arrhythmias. <i>British Journal of Pharmacology</i> , 2014 , 171, 5665-81	8.6	31
77	Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. <i>International Journal of Cardiology</i> , 2014 , 174, 360-7	3.2	47
76	Protective effects elicited by levosimendan against liver ischemia/reperfusion injury in anesthetized rats. <i>Liver Transplantation</i> , 2014 , 20, 361-75	4.5	41
75	Efficacy of selective NCX inhibition by ORM-10103 during simulated ischemia/reperfusion. <i>European Journal of Pharmacology</i> , 2014 , 740, 539-51	5.3	11
74	Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus. <i>Journal of Cardiovascular Pharmacology</i> , 2014 , 64, 199-208	3.1	17
73	Discovery and structural characterization of a phospholamban-binding cyclic peptide and design of novel inhibitors of phospholamban. <i>Chemical Biology and Drug Design</i> , 2013 , 81, 463-73	2.9	2
72	Lessons from Lisbon on AHF drug treatment: is it really true that all-old-failed-all-new-will-succeed?. <i>International Journal of Cardiology</i> , 2013 , 168, 4798-9	3.2	2
71	Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo. <i>Pharmacological Reports</i> , 2013 , 65, 1304-10	3.9	14
70	Renal effects of levosimendan: a consensus report. <i>Cardiovascular Drugs and Therapy</i> , 2013 , 27, 581-90	3.9	55

69	ORM-10103, a novel specific inhibitor of the Na ⁺ /Ca ²⁺ exchanger, decreases early and delayed afterdepolarizations in the canine heart. <i>British Journal of Pharmacology</i> , 2013 , 170, 768-78	8.6	47
68	Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. <i>International Journal of Cardiology</i> , 2012 , 159, 82-7	3.2	209
67	Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy. <i>Advances in Therapy</i> , 2012 , 29, 1037-50	4.1	12
66	Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012 , 342, 376-88	4.7	57
65	Prolonged antispasmodic effect in isolated radial artery graft and pronounced platelet inhibition induced by the inodilator drug, levosimendan. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012 , 110, 269-74	3.1	11
64	The clinical effects of levosimendan are not attenuated by sulfonylureas. <i>Scandinavian Cardiovascular Journal</i> , 2012 , 46, 330-8	2	4
63	Absence of mitochondrial activation during levosimendan inotropic action in perfused paced guinea pig hearts as demonstrated by modular control analysis. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2010 , 299, R786-92	3.2	12
62	Effects of levosimendan on the energy balance: preclinical and clinical evidence. <i>Journal of Cardiovascular Pharmacology</i> , 2009 , 53, 302-10	3.1	32
61	A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. <i>British Journal of Pharmacology</i> , 2008 , 154, 41-50	8.6	81
60	Calcium Sensitizer Levosimendan and Its Use in Acute Heart Failure and Related Conditions 2008 , 595-607		1
59	Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. <i>British Journal of Pharmacology</i> , 2007 , 150, 851-61	8.6	52
58	The cardioprotective effects of levosimendan: preclinical and clinical evidence. <i>Journal of Cardiovascular Pharmacology</i> , 2007 , 50, 257-63	3.1	66
57	Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006 , 290, H2007-14	5.2	9
56	The presence of Lys27 instead of Asn27 in human phospholamban promotes sarcoplasmic reticulum Ca ²⁺ -ATPase superinhibition and cardiac remodeling. <i>Circulation</i> , 2006 , 113, 995-1004	16.7	35
55	Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006 , 11, 129-35	2.6	29
54	Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model. <i>Journal of Cardiovascular Pharmacology</i> , 2006 , 48, 148-52	3.1	39
53	Positive inotropic effect of levosimendan is correlated to its stereoselective Ca ²⁺ -sensitizing effect but not to stereoselective phosphodiesterase inhibition. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006 , 98, 74-8	3.1	16
52	The effect of levosimendan during long-term amiodarone treatment in dogs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006 , 99, 27-32	3.1	1

51	The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. <i>British Journal of Pharmacology</i> , 2006 , 148, 696-702	8.6	59
50	Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. <i>Cardiovascular Drug Reviews</i> , 2005 , 23, 71-98		73
49	Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone. <i>Journal of Cardiovascular Pharmacology</i> , 2005 , 46, 369-76	3.1	37
48	Structure of the exopolysaccharide produced by <i>Enterobacter amnigenus</i> . <i>Carbohydrate Research</i> , 2005 , 340, 439-47	2.9	29
47	A cellular UDP-glucose deficiency causes overexpression of glucose/oxygen-regulated proteins independent of the endoplasmic reticulum stress elements. <i>Journal of Biological Chemistry</i> , 2004 , 279, 21724-31	5.4	37
46	The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. <i>European Journal of Pharmacology</i> , 2004 , 486, 67-74	5.3	79
45	Stereoselective binding of levosimendan to cardiac troponin C causes Ca ²⁺ -sensitization. <i>European Journal of Pharmacology</i> , 2004 , 486, 1-8	5.3	45
44	Potassium-specific effects of levosimendan on heart mitochondria. <i>Biochemical Pharmacology</i> , 2004 , 68, 807-12	6	77
43	The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitizer, with cardiac troponin c. <i>Molecular and Cellular Biochemistry</i> , 2004 , 266, 87-107	4.2	75
42	ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. <i>Current Opinion in Critical Care</i> , 2004 , 10, 436-41	3.5	48
41	Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion. <i>Journal of Cardiovascular Pharmacology</i> , 2004 , 44, 316-21	3.1	28
40	Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. <i>Journal of Cardiovascular Pharmacology</i> , 2004 , 43, 555-61	3.1	65
39	Complete structure analysis of OR-1746, a complex product of cyclocondensation of arylhydrazomalononitriles containing clusters of protonated and unprotonated nitrogens, by pulsed-field-gradient heteronuclear NMR. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003 , 31, 125-31	3.5	3
38	Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. <i>Journal of Molecular and Cellular Cardiology</i> , 2003 , 35, 1055-61	5.8	44
37	Structural and functional implications of the phospholamban hinge domain: impaired SR Ca ²⁺ uptake as a primary cause of heart failure. <i>Cardiovascular Research</i> , 2002 , 56, 248-59	9.9	37
36	Structure of the 1-36 N-terminal fragment of human phospholamban phosphorylated at Ser-16 and Thr-17. <i>Biophysical Journal</i> , 2002 , 83, 484-90	2.9	14
35	Improved survival with simendan after experimental myocardial infarction in rats. <i>European Journal of Pharmacology</i> , 2001 , 419, 243-8	5.3	35
34	Levosimendan is a mitochondrial K(ATP) channel opener. <i>European Journal of Pharmacology</i> , 2001 , 428, 311-4	5.3	103

33	Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. <i>Journal of Biological Chemistry</i> , 2001 , 276, 9337-43	5.4	101
32	Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. <i>Journal of Cardiovascular Pharmacology</i> , 2001 , 37, 367-74	3.1	128
31	Conformations of the regulatory domain of cardiac troponin C examined by residual dipolar couplings. <i>FEBS Journal</i> , 2000 , 267, 6665-72		20
30	Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan. <i>Journal of Molecular and Cellular Cardiology</i> , 2000 , 32, 479-91	5.8	73
29	Regulation of total mitochondrial Ca ²⁺ in perfused liver is independent of the permeability transition pore. <i>American Journal of Physiology - Cell Physiology</i> , 1999 , 276, C1297-302	5.4	21
28	Structural determination of the acidic exopolysaccharide produced by a <i>Pseudomonas</i> sp. strain 1.15. <i>Carbohydrate Research</i> , 1999 , 315, 159-68	2.9	44
27	Structure of the 1-36 amino-terminal fragment of human phospholamban by nuclear magnetic resonance and modeling of the phospholamban pentamer. <i>Biophysical Journal</i> , 1999 , 76, 1784-95	2.9	53
26	Structural investigation of the exopolysaccharide produced by <i>Pseudomonas flavescens</i> strain B62--degradation by a fungal cellulase and isolation of the oligosaccharide repeating unit. <i>FEBS Journal</i> , 1998 , 251, 971-9		19
25	31P NMR analysis of phospholipids in crude extracts from different sources: improved efficiency of the solvent system 1998 , 36, 907-912		27
24	Sensitivity of chondrocytes of growing cartilage to reactive oxygen species. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1998 , 1425, 103-11	4	18
23	Solution structure and main chain dynamics of the regulatory domain (Residues 1-91) of human cardiac troponin C. <i>Journal of Biological Chemistry</i> , 1998 , 273, 15633-8	5.4	36
22	Cellular UDP-glucose deficiency caused by a single point mutation in the UDP-glucose pyrophosphorylase gene. <i>Journal of Biological Chemistry</i> , 1997 , 272, 23784-91	5.4	66
21	Noninvasive in vivo quantitative assessment of fat content in human liver. <i>Journal of Hepatology</i> , 1997 , 27, 108-13	13.4	259
20	Organic solvent systems for 31P nuclear magnetic resonance analysis of lecithin phospholipids: applications to two-dimensional gradient-enhanced 1H-detected heteronuclear multiple quantum coherence experiments. <i>Analytical Biochemistry</i> , 1997 , 245, 38-47	3.1	56
19	Analysis of total lipid extracts from human liver by 13C and 1H nuclear magnetic resonance spectroscopy. <i>Analytical Biochemistry</i> , 1996 , 236, 41-8	3.1	32
18	Cloning of the yeast ATP3 gene coding for the β subunit of F1 and characterization of atp3 mutants.. <i>Journal of Biological Chemistry</i> , 1995 , 270, 2880	5.4	27
17	Oxygen-derived free radical (ODFR) action on hyaluronan (HA), on two HA ester derivatives, and on the metabolism of articular chondrocytes. <i>Experimental Cell Research</i> , 1995 , 218, 79-86	4.2	54
16	Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. <i>Journal of Magnetic Resonance Imaging</i> , 1995 , 5, 281-5	5.6	305

15	Detection and quantitation of phosphorus metabolites in crude tissue extracts by ¹ H and ³¹ P NMR: use of gradient assisted ¹ H- ³¹ P HMQC experiments, with selective pulses, for the assignment of less abundant metabolites. <i>NMR in Biomedicine</i> , 1995 , 8, 190-6	4.4	11
14	Changed Relation between Phosphorylation Potential and Left Ventricular Developed Pressure in Guinea Pig Hearts during Ischemia-Reperfusion a. <i>Annals of the New York Academy of Sciences</i> , 1994 , 723, 495-502	6.5	1
13	Energy metabolism, replicative ability, intracellular calcium concentration, and ionic channels of horse articular chondrocytes. <i>Experimental Cell Research</i> , 1994 , 210, 130-6	4.2	18
12	¹ H NMR spectroscopic studies of lipid extracts from human fatty liver. <i>Biochemical and Biophysical Research Communications</i> , 1993 , 192, 1217-22	3.4	18
11	Hyaluronan can be protected from free-radical depolymerisation by 2,6-diisopropylphenol, a novel radical scavenger. <i>Biochemical and Biophysical Research Communications</i> , 1993 , 193, 927-33	3.4	26
10	Analysis of lipids in crude extracts by ¹³ C nuclear magnetic resonance. <i>Analytical Biochemistry</i> , 1993 , 214, 238-44	3.1	11
9	Inhibition of lipid peroxidation in isolated rat liver mitochondria by the general anaesthetic propofol. <i>Biochemical Pharmacology</i> , 1992 , 44, 391-3	6	74
8	Lipid extracts from different algal species: ¹ H and ¹³ C-NMR spectroscopic studies as a new tool to screen differences in the composition of fatty acids, sterols and carotenoids. <i>Journal of Applied Phycology</i> , 1992 , 4, 315-322	3.2	15
7	¹ H- and ¹³ C-NMR spectroscopic studies of lipid extracts of the red alga <i>Gracilaria longa</i> . <i>Journal of Applied Phycology</i> , 1992 , 4, 149-155	3.2	5
6	³¹ P NMR studies of resting zone cartilage from growth plate. <i>Magnetic Resonance in Medicine</i> , 1992 , 25, 355-61	4.4	17
5	Energy state of chondrocytes assessed by ³¹ P-NMR studies of preosseous cartilage. <i>Biochemical and Biophysical Research Communications</i> , 1991 , 180, 216-22	3.4	29
4	¹ H-NMR studies of lipid extracts of rat liver mitochondria. <i>Biochemical and Biophysical Research Communications</i> , 1991 , 179, 904-11	3.4	17
3	Modification of plasma membrane of differentiating preosseous chondrocytes: evidence for a degradative process in the mechanism of matrix vesicle formation. <i>Experimental Cell Research</i> , 1990 , 188, 214-8	4.2	12
2	Possible mechanism of inhibition of cartilage alkaline phosphatase by insulin. <i>Acta Diabetologica Latina</i> , 1989 , 26, 321-7		6
1	Biochemical and immunohistochemical evidence that in cartilage an alkaline phosphatase is a Ca ²⁺ -binding glycoprotein. <i>Journal of Cell Biology</i> , 1986 , 103, 1615-23	7.3	131